Together with SOX11 and TP53 expression, PAX5 may enhance the stratification of MCL patients, as those with triple-positive expression exhibited inferior progression-free survival (PFS) and overall survival (OS), independent of the Mantle Cell Lymphoma International Prognostic Index (MIPI), Ki-67 levels, and TP53 mutation status [103]. This evidence concerns the gene TP53 and mantle cell lymphoma.